RxSight Inc. (RXST) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, RxSight Inc. (NASDAQ: RXST) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $5.05 (+3.06% 1D, market cap $210.0M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RXST ranks #819 in composite RQD confidence.
Within the Health Care sector (Ophthalmic Goods), RXST carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 76.6%, and ROIC of -14.9%. By comparison, STAA (STAAR Surgical Company) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $1.27B) and EYE (National Vision Holdings Inc.) posts a C+ grade (68/100 RQD, P/E 44.4x, ROIC 4.4%, cap $1.32B). Among the 5-stock peer group, EYE leads on earnings multiple (44.4x) while EYE leads on capital efficiency (4.4% ROIC).
Per RXST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001111485), RxSight Inc. generated $134.5M in revenue (-3.9% YoY), -$39 in net income, and -$19.3M in free cash flow against $311.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±10.9% realized swing band)
FRED Regime × Technicals: 7% of 52W Range • RSI-14 at 46.6 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While RXST currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.39) and Max Pain ($5.30) forces dealer call-delta covering toward $13.88.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
RxSight Inc. (RXST) surged +3.06% to $5.05, trading at 7% of its 52-week range ($4.4 – $13.22). Stretched risk/reward at current multiples (-15% return on capital) under elevated 10-year interest-rate pressure.
ALISO VIEJO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on October 23, 2026, RxSight granted inducement stock options to purchase a total of 236,456 shares of RxSight’s co
ALISO VIEJO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that it will report financial results for the third quarter of 2026 after the market close on Tuesday, November 3, 20
ALISO VIEJO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced the appointments of Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice President of Sales and
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -3.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RXST today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RXST. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, RxSight Inc. (RXST) ranks #819 by composite RQD confidence (35/100, grade D-) and #569 by equity capitalization ($210.0M). Within this direct 5-issuer industry benchmark cohort, EYE leads on earnings valuation at 44.4x trailing P/E, while EYE leads on capital efficiency and profitability with 4.4% ROIC and — gross margin. EYE currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with RXST at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RXST
ACTIVE
RxSight Inc. | D- | 35/100 | — | 76.6% | -14.9% | +3.06% | $210.0M | Benchmark Subject |
| STAA STAAR Surgical Company | D- | 38/100 | — | 76.2% | -35.0% | +2.56% | $1.27B | /staa-vs-rxst → |
| EYE National Vision Holdings Inc. | C+ | 68/100 | 44.4x | — | 4.4% | +7.63% | $1.32B | /eye-vs-rxst → |
| WRBY Warby Parker Inc. | D+ | 52/100 | — | 54.0% | -1.7% | +0.66% | $3.04B | /wrby-vs-rxst → |
| LUCY Innovative Eyewear Inc. | D- | 42/100 | — | 21.3% | -35.0% | -3.43% | $7.2M | /lucy-vs-rxst → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), RxSight Inc. (RXST) reported GAAP revenue of $134.5M (-3.9% vs. FY2024 revenue of $139.9M , and +51.0% cumulative change since FY2023) , GAAP net income of -$39, operating cash flow of -$15.5M, and free cash flow of -$19.3M (+13.6% YoY). On the balance sheet, RXST closed FY2025 with $311.8M in total assets against $0 in total debt (Altman Z-Score: 1.45, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $134.5M | -$39 | -$15.5M | -$19.3M | $311.8M | — |
| FY2024 (FY) | 2024-12-31 | $139.9M | -$27 | -$16.9M | -$22.4M | $318.6M | — |
| FY2023 (FY) | 2023-12-31 | $89.1M | -$49 | -$41.6M | -$41.6M | — | — |
As of 2026-11-01, RxSight Inc. (NASDAQ: RXST) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $5.05 (+3.06% 1D, market cap $210.0M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RXST ranks #819 in composite RQD confidence.
Within the Health Care sector (Ophthalmic Goods), RXST carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 76.6%, and ROIC of -14.9%. By comparison, STAA (STAAR Surgical Company) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $1.27B) and EYE (National Vision Holdings Inc.) posts a C+ grade (68/100 RQD, P/E 44.4x, ROIC 4.4%, cap $1.32B). Among the 5-stock peer group, EYE leads on earnings multiple (44.4x) while EYE leads on capital efficiency (4.4% ROIC).
Per RXST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001111485), RxSight Inc. generated $134.5M in revenue (-3.9% YoY), -$39 in net income, and -$19.3M in free cash flow against $311.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
RXST last traded at $5.05 (+3.06% on volume of 841,608 shares), positioning the stock -6.31% below its 50-day simple moving average ($5.39) and -20.72% below its 200-day simple moving average ($6.37). Across its 52-week range of $4.40 to $13.22, RXST sits at the 7.4% percentile with a 14-day RSI of 46.6 (NEUTRAL RANGE) and an implied next-earnings move of ±10.9% ($4.50 to $5.60).
Why RXST Stock surged +3.06% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-15% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.